These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy. Genazzani AR; Gadducci A; Gambacciani M Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941 [TBL] [Abstract][Full Text] [Related]
24. Different approaches in contraception. Runnebaum B; Rabe T; Kiesel L Contracept Deliv Syst; 1984 Jul; 5(3):15 p. PubMed ID: 12266639 [TBL] [Abstract][Full Text] [Related]
25. [Teratogenic and mutagenic risks of radiotherapy: when and how to prescribe contraception]. Marty M; Mignot L; Gisselbrecht G; Morvan F; Gorins A; Boiron M Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):181-6. PubMed ID: 12280202 [TBL] [Abstract][Full Text] [Related]
26. [Contraception at risk]. Dubois C; Le Strat N Rev Prat; 1987 Sep; 37(38):2293-301. PubMed ID: 3659796 [TBL] [Abstract][Full Text] [Related]
27. Status of generic substitution: problematic drug classes reviewed. Ross MB Hosp Formul; 1989 Aug; 24(8):441-4, 447-9. PubMed ID: 10294356 [TBL] [Abstract][Full Text] [Related]
28. The state of the contraceptive art. Tyrer LB; Duarte J Plan Parent Rev; 1983; 3(2):5-7. PubMed ID: 12265618 [TBL] [Abstract][Full Text] [Related]
29. Current approaches to the use of generic antiepileptic drugs. Krämer G; Biraben A; Carreno M; Guekht A; de Haan GJ; Jedrzejczak J; Josephs D; van Rijckevorsel K; Zaccara G Epilepsy Behav; 2007 Aug; 11(1):46-52. PubMed ID: 17537678 [TBL] [Abstract][Full Text] [Related]
32. [Pros and cons of triphasic oral contraception]. Berdah J Contracept Fertil Sex (Paris); 1985 Dec; 13(12):1205-10. PubMed ID: 12267512 [TBL] [Abstract][Full Text] [Related]
33. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300 [TBL] [Abstract][Full Text] [Related]
35. [Potential advantages of triphasic combined oral contraceptives in the light of recent epidemiological and endocrinometabolic data]. Gaspard U; Dubois M Contracept Fertil Sex (Paris); 1982 Sep; 10(9):551-60. PubMed ID: 12311606 [TBL] [Abstract][Full Text] [Related]
36. The debate over substitution policy. Its evolution and scientific basis. Schwartz LL Am J Med; 1985 Aug; 79(2B):38-44. PubMed ID: 3898831 [TBL] [Abstract][Full Text] [Related]
37. The formulation of oral contraceptives: does the amount of estrogen make any clinical difference? Speroff L Johns Hopkins Med J; 1982 May; 150(5):170-6. PubMed ID: 7043035 [TBL] [Abstract][Full Text] [Related]
38. Generic vs. brand name drugs--defining and enforcing standards. Lasagna LC Internist; 1979 May; 20(4):11, 13. PubMed ID: 10316827 [No Abstract] [Full Text] [Related]
39. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Stefanick ML Am J Med; 2005 Dec; 118 Suppl 12B():64-73. PubMed ID: 16414329 [TBL] [Abstract][Full Text] [Related]